Intellia Therapeutics (NASDAQ:NTLA) Receives Buy Rating from Truist Financial

Truist Financial restated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research note released on Monday, Benzinga reports. Truist Financial currently has a $120.00 target price on the stock.

Other research analysts also recently issued reports about the company. BMO Capital Markets raised their price objective on Intellia Therapeutics from $62.00 to $70.00 and gave the stock an outperform rating in a report on Friday, May 10th. Wedbush restated a neutral rating and set a $29.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. StockNews.com upgraded Intellia Therapeutics to a sell rating in a report on Friday, May 10th. Cantor Fitzgerald restated an overweight rating and set a $65.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, June 18th. Finally, Citigroup reduced their price objective on Intellia Therapeutics from $31.00 to $29.00 and set a neutral rating on the stock in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $69.00.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $22.91 on Monday. Intellia Therapeutics has a 52-week low of $19.37 and a 52-week high of $46.50. The firm has a market capitalization of $2.21 billion, a P/E ratio of -4.27 and a beta of 1.84. The stock has a 50 day moving average price of $23.70 and a 200 day moving average price of $26.38.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The firm had revenue of $28.94 million during the quarter, compared to analyst estimates of $15.60 million. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. As a group, sell-side analysts forecast that Intellia Therapeutics will post -4.98 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. Janney Montgomery Scott LLC grew its stake in Intellia Therapeutics by 128.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 11,862 shares of the company’s stock worth $375,000 after buying an additional 6,666 shares during the last quarter. Rhumbline Advisers lifted its position in Intellia Therapeutics by 1.0% during the 3rd quarter. Rhumbline Advisers now owns 163,985 shares of the company’s stock worth $5,185,000 after acquiring an additional 1,578 shares during the period. Hsbc Holdings PLC acquired a new stake in Intellia Therapeutics during the 3rd quarter worth about $635,000. Profund Advisors LLC lifted its position in Intellia Therapeutics by 12.8% during the 3rd quarter. Profund Advisors LLC now owns 40,461 shares of the company’s stock worth $1,279,000 after acquiring an additional 4,592 shares during the period. Finally, Corton Capital Inc. lifted its position in Intellia Therapeutics by 91.7% during the 3rd quarter. Corton Capital Inc. now owns 14,088 shares of the company’s stock worth $445,000 after acquiring an additional 6,740 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.